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Synopsis 
Use of metal based anticancer medication began with the clinical approval of cisplatin in 1978. 
Research led to the development of six platinum based drug candidates which are in use around 
the world. However there is a great need to develop better treatment strategies. The present work 
entitled “Cytotoxicity of Metal Based Anticancer Active Complexes and Their Targeted Delivery 
Using Nanoparticles” is an effort to prepare cytotoxic metal complexes based on platinum(IV) 
and copper(II) and deliver them selectively to cancer cells using a targeting ligand, biotin, with 
two different delivery vehicles, viz. PEGylated polyamidoamine dendrimer (PAMAM) and gold 
nanoparticles (AuNPs). 
Chapter 1 provides a brief introduction to cancer and its characteristic features, followed by a 
short description about different treatment modalities in clinical practice. An account of the 
development of anticancer drugs starting from purely organic drugs to the field of metal based 
anticancer drugs is discussed. An overview of the available targeting strategies are discussed with 
specific examples. The section ends with the scope of the present work. 
Platinum based anticancer drugs currently in use contain platinum in the +2 oxidation state. These 
drugs showed side effects and are often ineffective against resistant cells, especially in the latter 
stages of treatment. A recent focus of metal based anticancer drug research is the development of 
platinum(IV) systems which shows promise to have greater activity in cancer cells in a reducing 
environment. Reported platinum(IV) dual drugs contain the components of “cisplatin” or an 
analogue along with an active organic drug. But there are no known dual drugs based on 
platinum(IV) that would generate a cytotoxic metal complex along with cisplatin. In Chapter 2, a 
bimetallic dual drug (M4) (Figure 1), the first of its kind, with components of cisplatin and copper 
bis(thiosemicarbazone) has been prepared (Figure 1). The components and the bimetallic complex 
were characterized using several spectroscopic techniques. The dual drug M4 was found to be 
highly cytotoxic (IC50 1.3 M) against HeLa cells and was better than cisplatin (IC50 6.8 M). The 
bimetallic complex turned out to be better than the mixture (IC50 7.2 M) of individual drugs which 
indicated possible synergism of the released cisplatin and the copper bis(thiosemicarbazone) from 
the dual drug. 
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Figure 1: Structure of the platinum(IV) and copper bis(thiosemicarbazone) complexes. 
A novel approach towards conjugation of platinum(IV) drugs to a carrier has been developed using 
a malonate moiety (Figure 2). The bis(butyric acid) complex, Pt(NH3)2(OCOC3H7)2Cl2 (M1), was 
taken as model complex to demonstrate the conjugation strategy. The complex M4 was also 
conjugated to the partially PEGylated 5th generation PAMAM dendrimers.  
 
Figure 2: Schematic representation of the platinum(IV) drug conjugated PAMAM dendrimer. 
The cytotoxicity of M4 was reduced to a small extent on conjugation to the dendrimer. In the 
presence of 5 mM sodium ascorbate as a reducing agent, sustained release (40 %) of the drug was 
shown to occur over a period of 48 h by the drug release study. The reduction in cytotoxicity of 
the dendrimer conjugates could be due to incomplete release of the active drug. Unfortunately, no 
enhanced activity was observed with the additional targeting ligand, biotin. The drug uptake study 
revealed that the dendrimer conjugates were successful in entering cancer cells. There was no 
preferential uptake with biotin conjugated dendrimers which explained the similar cytotoxicity of 
dendrimer conjugates with and without biotin. 
Different delivery vehicles showed varied efficiency in delivering the pay load (drugs) to the 
cancer site. In this connection, PEGylated gold nanoparticles have shown good promise as a drug 
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delivery vehicle. In Chapter 3, M1 and M4 are both conjugated to malonate functionalized 
PEGylated gold nanoparticles (30 nm). Biotin was also attached to the AuNPs for targeting HeLa 
cells. 
 
Figure 3: Schematic representation of the platinum(IV) drug and biotin conjugated AuNPs. 
The AuNPs were highly stable in water without agglomeration. There was no shift in the Surface 
Plasmon Resonance (SPR) band after conjugation of the drug molecules and targeting ligands. 
TEM images and DLS measurements showed there was no change in particle size. Drug 
conjugated AuNPs were also very stable in high salt concentrations as well as over a large range 
of pH. AuNPs with M1 were found to be less cytotoxic than the parent drug. Biotinylated AuNPs 
with M1 were more potent than non-biotinylated nanoparticles and increased cytotoxicity (35 %) 
was observed with biotin conjugation. Surprisingly, the enhanced activity of biotinylated AuNPs 
could not be correlated to the drug uptake study. The cytotoxicity of the bimetallic dual drug 
containing AuNPs were about 10-fold less and no increased activity was observed with the 
biotinylated conjugates. The reduced activity of AuNPs with the bimetallic drug was due to 
incomplete release from the AuNPs (20 % release after 48 h). But the release kinetics was very 
slow and sustained which might increase in vivo activity. The unexpected lower activity of 
biotinylated conjugates with copper bis(thiosemicarbazone) was suggestive of interference 
between bis(thiosemicarbazone) complex and the biotin receptor resulting in reduced drug uptake. 
Copper bis(thiosemicarbazone) complexes hold very good promise as a class of non-platinum 
anticancer drug candidates. However, they lack selectivity towards malignant cells. Recently, 
CuATSM has shown hypoxia selectivity and very good cytotoxicity resulting in 64CuATSM being 
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used in advanced stages of clinical trials for imaging hypoxic cells. In Chapter 4, a copper 
bis(thiosemicarbazone) complex analogous to Cu(ATSM) with a redox active cleavable disulfide 
linker and a terminal carboxylic acid group (CuATSM-SS-COOH) was synthesised and 
characterised spectroscopically. The complex was highly cytotoxic and has an IC50 value (6.9 M) 
similar to that of cisplatin against HeLa cells. The complex was conjugated to PEGylated gold 
nanoparticles by amide coupling between the acid group from the drug molecule and the amine on 
the AuNPs (20 nm) for smart drug delivery. The gold nanoparticles were decorated with biotin for 
targeted delivery to the HeLa cells.  
 
Figure 4: Schematic representation of the CuATSM-SS-COOH and biotin decorated AuNPs. 
The CuATSM-SS-COOH was insoluble in water but conjugation to PEGylated gold 
nanoparticles made it water soluble. The drug molecules and biotin conjugated AuNPs were highly 
stable which was confirmed by TEM and DLS measurements. Similar to the study described in 
the previous chapter, these AuNPs were also stable in a wide range of pH and salt concentrations. 
In vitro glutathione (GSH) triggered release study demonstrated substantial release of the cytotoxic 
agent from the AuNPs (60 %) over a period of 48 h. In vitro cell viability study with HeLa cells 
showed reduced cytotoxicity (IC50 15 M) of AuNPs with and without biotin containing drug 
conjugates relative to the parent copper complex (IC50 6.9 M). The reduction of the cytotoxicity 
correlated well with the released amount of the active drug from the nanoconjugates over the same 
time period. In vivo studies demonstrated the effectiveness of these nanoparticle carriers as suitable 
vehicles as they exhibited nearly four-fold reduction of tumor volume without significant loss in 
body weight. Moreover, the biotin targeted nanoparticle showed significant (p < 0.5) reduction in 
tumor volume compared to the non-targeted gold nanoparticles. Thus, this smart linking strategy 
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can be extended to other cytotoxic complexes that suffer from non-specificity, low aqueous 
solubility and toxicity. 
Multinuclear anticancer active complexes do not act in the same way as that of their corresponding 
mononuclear analogues. In the case of multinuclear platinum complexes, the activity not only 
depends on the active moiety but also on the spacer length between the moieties. In Chapter 5, a 
series of multinuclear copper bis(thiosemicarbazone) complexes were prepared and characterised 
using different techniques.  
 
Figure 5: General structures of binuclear copper bis(thiosemicarbazone) complexes. 
All the complexes showed redox activity and have a very high negative reduction potential, i.e. 
these compounds would not be easily reduced in the biological medium and would remain as 
copper(II) species. As the concentration of the reducing agents are more within cancer cells, once 
these complexes are inside cells they would be reduced to Cu(I). These compounds were shown 
to be highly lipophilic from the large log P values. Unfortunately, these binuclear complexes were 
less active than similar mononuclear complexes. One possible reason for the reduced cytotoxicity 
of these complexes could be adherence of the complexes to the cell membrane due to the high 
lipophilicity of these complexes. Out of five different methylene spacers between two 
bis(thiosemicrarbazone) moieties, the complex with a three carbon spacer was shown to be the 
most active against HeLa cells. The complexes with five and six methylene spacers turn out to be 
noncytotoxic. Further experiments are necessary to reveal the mechanism of action in these 
complexes.    
In summary, bimetallic complexes can be very active and may be a way of overcoming drug 
resistance in platinum based therapy. A dual drug can be delivered using a malonate moiety and a 
disulfide linker. Gold nanoparticles are good delivery vehicles for these dual drugs and show great 
potential for improvement and translation to the next stage. 
